Furthermore, the total area of GFAP-positive expression (Figure 6(c)) and the integral optical density (IOD) (Figure 6(d)) were significantly increased in the AD model compared to those of the sham group (1448.5 ± 438.2 versus 759.9 ± 61.0 μm2; 344.6 ± 82.0 versus 221.9 ± 33.87) (P < 0.05, P < 0.01), and these changes were partly reversed after β-asarone treatment. The gene discussed is GFAP; the disease is Alzheimer disease.